Skip to content
naulon

Not checkedNot checked for notices yet.

First-in-human phase Ia study of the PI3Kα inhibitor CYH33 in patients with solid tumors

Xiao-Li Wei, Fu-Rong Liu, Ji-Hong Liu and 11 more

Nature Communications · 2022

doi:10.1038/s41467-022-34782-9 (opens in a new tab)

We email you when a new notice or a question about this paper appears.

Abstract

PIK3CA is a commonly mutated cancer-associated gene, making it an attractive therapeutic target. Here, the authors report the results of a first-in-human phase Ia trial to assess the safety and recommended phase II dose of CYH33, a PI3Kα inhibitor, in patients with advanced solid tumors.

Abstract licence: CC BY-NC-ND

References36

  1. 1.
  2. 28.

34 more references, whose wording the paper’s licence keeps private.

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.